Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 38

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 38
---
 final and nonappealable or imposes, as a final and nonappealable condition. See “ The Merger Agreement—Termination.”

The price of MIRA’s common stock is subject to fluctuations

The market price of MIRA Common Stock is subject to general price fluctuations in the market for publicly traded equity securities and has experienced volatility in the past. Stock price changes may result from a variety of factors, including, among others, general market and economic conditions, changes in the businesses, operations and prospects of MIRA, and an evolving regulatory landscape. Market assessments of the benefits of the Merger and the likelihood that the Merger will be completed, as well as general and industry specific market and economic conditions, may also impact the market price of MIRA Common Stock. Many of these factors are beyond MIRA’s control. You are encouraged to obtain current market price quotations for MIRA Common Stock before you determine how to vote on the Merger.

There has been no public market for SKNY Common Stock and the lack of a public market may make it more difficult to determine the fair market value of SKNY than if there were such a public market.

The outstanding shares of SKNY Common Stock are privately held and are not traded on any public market. The lack of a public market makes it more difficult to determine the fair market value of SKNY than if the outstanding shares of SKNY Comon Stock were traded publicly. The value ascribed to SKNY in the Merger and in the Merger Consideration may not be indicative of the price at which the outstanding shares of SKNY Common Stock may have traded on a public market if such were available. The Merger Consideration to be paid to SKNY stockholders was determined based on negotiations between MIRA and SKNY and not on the basis of market prices. The relative values of MIRA and SKNY may not be indicative of the price at which the shares of SKNY Common Stock may have been traded on a public market.

SKNY may fail to expand its manufacturing capability in time to meet market demand for SKNY’s products and product candidates, and the FDA may refuse to accept SKNY’s facilities or those of its contract manufacturers as being suitable for the production of SKNY’s products and product candidates. Any problems in SKNY’s manufacturing process could have a material adverse effect on MIRA’s business, results of operations and financial condition.

Before SKNY can begin commercial manufacture of any product candidates for sale in the U.S., it must obtain FDA regulatory approval for the product,